相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study
Francesco Spannella et al.
INTERNAL AND EMERGENCY MEDICINE (2019)
Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials
Qiang Geng et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Akshay S. Desai et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?
Kevin S. Shah et al.
CURRENT HYPERTENSION REPORTS (2019)
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation PRIME Study
Duk-Hyun Kang et al.
CIRCULATION (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial
Richard Haynes et al.
CIRCULATION (2018)
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease
Matthew James et al.
CIRCULATION (2018)
Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug
Guillermo Gervasini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor
Surya P. Ayalasomayajula et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
What Physicians Need to Know About Renal Function in Outpatients with Heart Failure
Bard Waldum-Grevbo
CARDIOLOGY (2015)
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
Adriaan A. Voors et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
Sadayoshi Ito et al.
HYPERTENSION RESEARCH (2015)
Neprilysin inhibition in chronic kidney disease
Parminder Judge et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
Lesley A. Inker et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis
Kevin Damman et al.
EUROPEAN HEART JOURNAL (2014)
Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency
Kevin Damman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
Patrick Rossignol et al.
CIRCULATION (2012)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade
Ron Blankstein et al.
Heart Failure Clinics (2008)
Losartan and end-organ protection-lessons from the RENAAL study
PR Kowey et al.
CLINICAL CARDIOLOGY (2005)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
JL Rouleau et al.
LANCET (2000)
分享论文
